MDA-MB-157Homo sapiens (Human)Cancer cell line

Also known as: MDA-MB157, MDAMB157, MDA-157, MDA157, MB 157, MB157, MD Anderson-Metastatic Breast-157, MDA-MB-15

🤖 AI SummaryBased on 10 publications

Quick Overview

Breast cancer cell line with complex chromosomal abnormalities and high proliferation rate.

Detailed Summary

MDA-MB-157 is a breast cancer cell line established from a metastatic pleural effusion. It exhibits rapid growth in dense plaques and suspension cultures, with a hypotriploid karyotype characterized by 64-66 chromosomes. The cell line shows epithelial morphology with features such as desmosomes and microvilli, and lacks contact inhibition. It has been used in studies related to breast cancer genetics, drug sensitivity, and tumor biology. The line is free from mycoplasma and viral contamination, and has been adapted to various culture media including RPMI-1640 and Ham's F-10 with fetal calf serum. Research on MDA-MB-157 has contributed to understanding the molecular mechanisms of breast cancer progression and therapeutic resistance.

Key Characteristics

Rapid proliferation in dense plaques and suspensionHypotriploid karyotype (64-66 chromosomes)Epithelial morphology with desmosomes and microvilliLack of contact inhibitionResistance to mycoplasma and viral contaminationAdaptation to multiple culture media
Generated on 6/15/2025

Basic Information

Database IDCVCL_0618
SpeciesHomo sapiens (Human)
Tissue SourcePleural effusion[UBERON:UBERON_0000175]

Donor Information

Age44
Age CategoryAdult
SexFemale
Raceblack_or_african_american
Subtype Featuresbasal_B TNBC

Disease Information

DiseaseBreast carcinoma
LineageBreast
SubtypeBreast Invasive Ductal Carcinoma
OncoTree CodeIDC

DepMap Information

Source TypeATCC
Source IDACH-000621_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleMSH6p.Pro42Ser (c.124C>T)Heterozygous-Unknown, PubMed=19593635
MutationSimpleMSH6p.Arg644Ser (c.1932G>C)Heterozygous-Unknown, PubMed=19593635
MutationSimpleTP53p.Pro87fs*53 (c.261_286del26) (p.Ala88Cysfs*52)Homozygous-Unknown, Unknown, PubMed=16541312

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10
D13S317
11
D16S539
11
D18S51
13,16
D19S433
13,14.2
D21S11
31,31.2
D2S1338
25
D3S1358
16
D5S818
12
D7S820
10,11
D8S1179
12,14
FGA
22,23
Penta D
3.2,9
Penta E
11
TH01
7,8
TPOX
9,11
vWA
15
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.

Lakhani S.R.

Breast Cancer Res. Treat. 167:289-301(2018).

Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile.

Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.

J. Proteome Res. 16:1391-1400(2017).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

Cell lines from human breast.";

Leibovitz A.

(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994).

Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.

Cailleau R.M., Olive M., Cruciger Q.V.J.

In Vitro 14:911-915(1978).

Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

Fogh J., Wright W.C., Loveless J.D.

J. Natl. Cancer Inst. 58:209-214(1977).

Mutations in p53 as potential molecular markers for human breast cancer.

Runnebaum I.B., Nagarajan M., Bowman M., Soto D., Sukumar S.

Proc. Natl. Acad. Sci. U.S.A. 88:10657-10661(1991).

Human tumor lines for cancer research.";

Fogh J.

Cancer Invest. 4:157-184(1986).

Breast tumor cell lines from pleural effusions.";

Cailleau R.M., Young R., Olive M., Reeves W.J. Jr.

J. Natl. Cancer Inst. 53:661-674(1974).

Establishment of epithelial cell line MDA-MB-157 from metastatic pleural effusion of human breast carcinoma.

Young R.K., Cailleau R.M., Mackay B., Reeves W.J. Jr.

In Vitro 9:239-245(1974).

Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.

Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.

Oncogene 16:2865-2878(1998).

Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping.

Isola J.J., Larsson C.

Genes Chromosomes Cancer 28:308-317(2000).

Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.

Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.

Cancer Res. 60:4519-4525(2000).

Molecular cytogenetic analysis of breast cancer cell lines.";

Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.

Br. J. Cancer 83:1309-1317(2000).

Aberrations of chromosome 8 in 16 breast cancer cell lines by comparative genomic hybridization, fluorescence in situ hybridization, and spectral karyotyping.

Isola J.J.

Cancer Genet. Cytogenet. 126:1-7(2001).

Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene.

Birnbaum D., Chaffanet M.

Genes Chromosomes Cancer 35:204-218(2002).

A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.

Edwards P.A.W., Chaffanet M.

Genes Chromosomes Cancer 37:333-345(2003).

The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells.

Domann F.E., Futscher B.W.

Neoplasia 6:187-194(2004).

Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.

Edwards P.A.W., Caldas C.

Carcinogenesis 26:923-930(2005).

BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.

van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.

Cancer Res. 66:41-45(2006).

Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.

Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.

Breast Cancer Res. Treat. 99:97-101(2006).

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.

Cancer Cell 10:515-527(2006).

Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.

Pollack J.R.

PLoS ONE 4:E6146-E6146(2009).

Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.

den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.

Breast Cancer Res. Treat. 121:53-64(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Lung cancer cell lines as tools for biomedical discovery and research.

Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.

J. Natl. Cancer Inst. 102:1310-1321(2010).

Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.

Chavez K.J., Garimella S.V., Lipkowitz S.

Breast Dis. 32:35-48(2010).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Rottapel R., Neel B.G., Moffat J.

Cancer Discov. 2:172-189(2012).

Molecular characterisation of cell line models for triple-negative breast cancers.

Reis-Filho J.S., Tutt A.

BMC Genomics 13:619.1-619.14(2012).

miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.

Martens J.W.M.

Breast Cancer Res. 15:R33.1-R33.17(2013).

Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.

McCormick F., Gray J.W.

Cancer Cell 24:450-465(2013).

Modeling precision treatment of breast cancer.";

Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.

Genome Biol. 14:R110.1-R110.14(2013).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

The proteomic landscape of triple-negative breast cancer.";

Irie H.Y., Lee S.-I., Blau C.A., Villen J.

Cell Rep. 11:630-644(2015).

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

OncoImmunology 3:e954893.1-e954893.12(2014).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).